Business
Aeterna Zentaris Successfully Reached a Key Milestone in the Non-Clinical Development of its Oral Prostate Cancer Vaccine Candidate, AEZS-120
Jul. 20, 2011 (Canada NewsWire Group) -- All amounts are in US dollars QUEBEC CITY, Jul...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n Jul. 20, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nAll amounts are in US dollars\n\n\nQUEBEC CITY, July 20, 2011 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the "Company") today announced that it has\n successfully reached a key milestone in the non-clinical development of\n its live recombinant prostate cancer vaccine candidate, AEZS-120, for\n oral administration. The program, partially funded through a grant from\n the German government, encompassed the full development of a GMP\n process, including GMP production and quality testing of a clinical\n batch, as well as a non-clinical safety and toxicology package, as\n previously agreed with regulatory authorities. Subject to a positive\n review by German regulatory authorities, the Company aims to start\n Phase I clinical development in 2012.\n\n\nThe principle of AEZS-120 is based on the recombinant expression and\n secretion of the prostate specific antigen (PSA) in the approved\n attenuated vaccine strain Salmonella typhi Ty21a using a proprietary technology. The technology allows for the\n expression and secretion of an antigen genetically coupled to the\n non-toxic B subunit of cholera toxin to enhance immunogenicity. In\n principle, this platform technology is suitable for any prophylactic or\n therapeutic vaccine indication by varying the antigen.\n\n\nAEZS-120 has been developed through a research collaboration with the\n Department of Medical Radiation Biology and Cel...